KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $28.9 million.

  • Neogenomics' Other Operating Expenses rose 3485.81% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.7 million, marking a year-over-year increase of 4436.93%. This contributed to the annual value of $91.3 million for FY2024, which is 2889.25% up from last year.
  • As of Q3 2025, Neogenomics' Other Operating Expenses stood at $28.9 million, which was up 3485.81% from $44.1 million recorded in Q2 2025.
  • Neogenomics' Other Operating Expenses' 5-year high stood at $44.1 million during Q2 2025, with a 5-year trough of $13.7 million in Q1 2021.
  • Over the past 5 years, Neogenomics' median Other Operating Expenses value was $17.6 million (recorded in 2023), while the average stood at $20.3 million.
  • Per our database at Business Quant, Neogenomics' Other Operating Expenses crashed by 88.83% in 2022 and then soared by 8998.32% in 2025.
  • Neogenomics' Other Operating Expenses (Quarter) stood at $15.9 million in 2021, then grew by 7.7% to $17.1 million in 2022, then grew by 5.43% to $18.1 million in 2023, then surged by 33.06% to $24.0 million in 2024, then grew by 20.15% to $28.9 million in 2025.
  • Its Other Operating Expenses was $28.9 million in Q3 2025, compared to $44.1 million in Q2 2025 and $22.7 million in Q1 2025.